Search Results - "Sniukiene, V."

First US-based phase 3 study of ulipristal acetate (UPA) for symptomatic uterine fibroids (UF): results of VENUS-I by Simon, J, Catherino, W.H, Segars, J, Blakesley, R, Chan, A, Sniukiene, V, Al-Hendy, A

Get full text

Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa‐2b/ribavirin by Gordon, S. C., Yoshida, E. M., Lawitz, E. J., Bacon, B. R., Sulkowski, M. S., Davis, M., Poordad, F., Bronowicki, J.‐P., Esteban, R., Sniukiene, V., Burroughs, M. H., Deng, W., Dutko, F. J., Brass, C. A., Albrecht, J. K., Rajender Reddy, K.

“…Summary Background Adherence to therapeutic regimens affects the efficacy of peginterferon alfa (P) and ribavirin (R) therapy in patients with chronic…”
Get full text

Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C by Xu, C., Gupta, S., Krishna, G., Cutler, D., Wirth, S., Galoppo, C., Ciocca, M., Kolz, K., Noviello, S., Sniukiene, V.

“…Purpose The aim of this study was to characterize the population pharmacokinetics of peginterferon (PEG-IFN) alfa-2b in pediatric patients with chronic…”
Get full text

449 OVERALL SAFETY PROFILE OF BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN by Manns, M.P, Felizarta, F, Schiff, E, Burroughs, M, Sniukiene, V, Boparai, N, Brass, C.A, Albrecht, J.K, Vierling, J.M

Get full text

422 PROJECTING THE CLINICAL IMPACT OF THERAPEUTIC REGIMENS INCLUDING BOCEPREVIR IN PREVIOUSLY UNTREATED ADULT SUBJECTS WITH CHRONIC HEPATITIS C GENOTYPE 1 by Ferrante, S, Chhatwal, J, Dasbach, E.J, El Khoury, A, Sniukiene, V, Poordad, F.F, Bronowicki, J.-P, Brass, C.A

Get full text

452 EFFICACY AMONG NORTH AMERICAN AND EUROPEAN HCV GENOTYPE-1 TREATMENT-NAIVE AND PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN by Marcellin, P, Vierling, J.M, Alric, L, Pirisi, M, Tran, A, Albrecht, J.K, Brass, C.A, Boparai, N, Sniukiene, V, Burroughs, M

Get full text

7 BOCEPREVIR IN ADDITION TO STANDARD OF CARE ENHANCED SVR IN HEPATITIS C VIRUS (HCV) GENOTYPE-1 WITH ADVANCED FIBROSIS/CIRRHOSIS: SUBGROUP ANALYSIS OF SPRINT-2 AND RESPOND-2 STUDIES by Bruno, S, Vierling, J.M, Esteban, R, Nyberg, L.M, Tanno, H, Albrecht, J.K, Brass, C.A, Boparai, N, Sniukiene, V, Burroughs, M

Get full text

1194 SUSTAINED VIROLOGIC RESPONSE AND BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS OBSERVED IN PATIENTS INFECTED WITH HCV GENOTPYPE 1A/1B WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN by Brass, C, Barnard, R.J.O, Howe, J.A, Ogert, R.A, Ralston, R, Boparai, N, Burroughs, M, Sniukiene, V, Mendez, P, Albrecht, J

Get full text

12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY by Poordad, F, Bronowicki, J.-P, Gordon, S.C, Zeuzem, S, Jacobson, I.M, Sulkowski, M.S, Poynard, T, Morgan, T.R, Burroughs, M, Sniukiene, V, Boparai, N, Brass, C.A, Albrecht, J.K, Bacon, B.R

Get full text

466 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 WHEN TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (PR) by Reddy, K.R, Bruno, S, Rossaro, L, Ravendhran, N, Pauly, M.P, Boparai, N, Sniukiene, V, Brass, C.A, Albrecht, J.K, Poordad, F, Jacobson, I.M

Get full text

428 ADHERENCE TO ASSIGNED DOSING REGIMEN AND SUSTAINED VIROLOGIC RESPONSE AMONG HEPATITIS C GENOTYPE 1 TREATMENT-NAIVE AND PEG/RIBAVIRIN TREATMENT-FAILURES TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN by Gordon, S.C, Lawitz, E.J, Bacon, B.R, Sulkowski, M.S, Yoshida, E.M, Davis, M, Boparai, N, Sniukiene, V, Burroughs, M, Brass, C.A, Albrecht, J.K, Reddy, K.R

Get full text

9 BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS (RAVS) ARE OBSERVED MORE FREQUENTLY IN HCV (GT1)-INFECTED PATIENTS WITH POOR RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN by Zeuzem, S, Barnard, R.J, Howe, J.A, Ogert, R.A, Ralston, R, Boparai, N, Brass, C.A, Albrecht, J.K, Burroughs, M, Sniukiene, V, Poordad, F, Gordon, S.C, Jacobson, I.M

Get full text

476 ANEMIA DURING TREATMENT WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN WITH OR WITHOUT BOCEPREVIR IS ASSOCIATED WITH HIGHER SVR RATES: ANALYSIS OF PREVIOUSLY UNTREATED AND PREVIOUS-TREATMENT-FAILURE PATIENTS by Sulkowski, M.S, Poordad, F, Manns, M.P, Bronowicki, J.-P, Reddy, K.R, Harrison, S.A, Afdhal, N.H, Boparai, N, Sniukiene, V, Burroughs, M, Albrecht, J.K, Brass, C.A, Jacobson, I.M

Get full text

481 FOUR-WEEK THERAPY WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN EFFECTIVELY PREDICTS SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE AND PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV-1 TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN by Vierling, J.M, Lawitz, E.J, Poordad, F, Sulkowski, M.S, Bourliere, M, Buti, M, Cooper, C, Galati, J.S, Albrecht, J.K, Boparai, N, Brass, C.A, Burroughs, M, Sniukiene, V, Bruno, S

Get full text

448 RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN REDUCES DURATION IN NAIVE AND PEGINTERFERON ALFA-2B/RIBAVIRIN PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV GENOTYPE 1 by Manns, M.P, Poordad, F, Bacon, B.R, Bruno, S, Esteban, R, Silva, M, Buti, M, Burroughs, M, Sniukiene, V, Boparai, N, Brass, C.A, Albrecht, J.K, Bronowicki, J.-P

Get full text

Ulipristal acetate improves health-related quality of life and reduces impact of symptoms due to uterine fibroids: results from venus I and II by Shulman, L., Lukes, A., Soper, D.E., Harrington, A., Sniukiene, V., Mo, Y., Gillard, P.

Get full text

Ulipristal acetate (UPA) treatment of uterine fibroids (UF): integrated liver safety results from venus I and II by Al-Hendy, A., Soper, D.E., Battucci, S., Mallick, M., Chan, A., Sniukiene, V., Liu, J.H.

Get full text

Ulipristal acetate (UPA) treatment of symptomatic uterine fibroids (UF): VENUS II subgroup analyses by race and BMI by Soper, D., Lukes, A.S., Gee, P., Kimble, T., Kroll, R., Mallick, M., Chan, A., Sniukiene, V., Shulman, L.P., Liu, J.

Get full text

VENUS II: the second us-based phase 3 study of ulipristal acetate (UPA) for treatment of symptomatic uterine fibroids (UF) by Liu, J., Soper, D., Lukes, A.S., Gee, P., Kimble, T., Kroll, R., Mallick, M., Chan, A., Sniukiene, V., Shulman, L.P.

Get full text

Quality of life with ulipristal acetate (UPA) treatment of symptomatic uterine fibroids (UF): VENUS II study by Kroll, R., Liu, J.H., Soper, D., Lukes, A.S., Gee, P., Kimble, T., Mallick, M., Gillard, P., Harrington, A., Sniukiene, V., Shulman, L.P.

Get full text